Skip to main content
. 2022 Sep 7;22:279. doi: 10.1186/s12935-022-02696-7

Table 2.

Examples of nanobodies that are currently being tested in clinical trials

Nanobodies compound Clinical use Target Stage References

Caplacizumab

ALX-0681

ALX-0081

Thrombotic thrombocytopenic purpura Ultra large von Willebrand factor Clinical trial phase III [129]
ALX-0171 Lower respiratory tract infection RSV (respiratory syncytial virus) Clinical trial phase I-II [128]
Bispecific nanobody-derived CAR-T cells Lymphoma

CD19

CD20

Clinical trial phase I [182]
[131I]-SGMIB anti-HER2 VHH1 Breast cancer HER2 Ongoing [114]